Source: Cancers. Unidades: FM, ICB
Subjects: IMUNOLOGIA, NEOPLASIAS CEREBRAIS, GLIOMA, IMUNOTERAPIA, ADJUVANTES IMUNOLÓGICOS, CÉLULAS DENDRÍTICAS, ASTROCITOMA, CÉLULAS CULTIVADAS DE TUMOR, VACINAÇÃO
ABNT
LEPSKI, Guilherme et al. Adjuvant vaccination with allogenic dendritic cells significantly prolongs overall survival in high-grade gliomas: results of a phase II trial. Cancers, v. 15, n. 4, p. 1-12, 2023Tradução . . Disponível em: https://doi.org/10.3390/cancers15041239. Acesso em: 20 ago. 2024.APA
Lepski, G., Bergami-Santos, P. C., Pinho, M. P., Chauca-Torres, N. E., Evangelista, G. C. M., Teixeira, S. F., et al. (2023). Adjuvant vaccination with allogenic dendritic cells significantly prolongs overall survival in high-grade gliomas: results of a phase II trial. Cancers, 15( 4), 1-12. doi:10.3390/cancers15041239NLM
Lepski G, Bergami-Santos PC, Pinho MP, Chauca-Torres NE, Evangelista GCM, Teixeira SF, Flatow E, Oliveira JV de, Fogolin C, Peres N, Arévalo A, Alves VAF, Barbuto JAM. Adjuvant vaccination with allogenic dendritic cells significantly prolongs overall survival in high-grade gliomas: results of a phase II trial [Internet]. Cancers. 2023 ; 15( 4): 1-12.[citado 2024 ago. 20 ] Available from: https://doi.org/10.3390/cancers15041239Vancouver
Lepski G, Bergami-Santos PC, Pinho MP, Chauca-Torres NE, Evangelista GCM, Teixeira SF, Flatow E, Oliveira JV de, Fogolin C, Peres N, Arévalo A, Alves VAF, Barbuto JAM. Adjuvant vaccination with allogenic dendritic cells significantly prolongs overall survival in high-grade gliomas: results of a phase II trial [Internet]. Cancers. 2023 ; 15( 4): 1-12.[citado 2024 ago. 20 ] Available from: https://doi.org/10.3390/cancers15041239